Imatinib is a selective tyrosine kinase inhibitor, successfully used for the treatment of chronic myelogenous leukaemia and gastrointestinal stromal tumors. Binding of drugs to proteins influence their pharmacokinetic and pharmacodynamics action. In the blood, the drug is distributed in the body in the free form or bound to plasma protein. Albumin and α-1 glycoprotein (AGP) are plasma proteins with the highest affinity for drug substances. Drugs which are weak acids mainly bind to plasma albumin, while drugs that are bases have affinity for α-1 glycoprotein. The main goal of this study is to quantitatively evaluate the interaction between imatinib mesylate (IMT) and α-1 glycoprotein to characterize the nature and forces underlying the formation of a molecular complex. Relaxation experiments provide quantitative information about the relationship between the binding affinity and structure of IMT. Thus, association constant was determined as Ka = 873.36 M-1. The ITC data revealed that the binding was an entropy driven process and the association constant Ka = 3.22 × 103 M-1, with a 1:1 stoichiometry. The results obtained by NMR and ITC were complemented with a molecular docking study.
Keywords: Drug binding; ITC calorimetry; Imatinib; Molecular docking; NMR; α-1 glycoprotein.
Copyright © 2020 Elsevier B.V. All rights reserved.